Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib, Dexamethasone, Doxorubicin, and ALCAR in Previously Treated Multiple Myeloma
NCT00581919Phase 2Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Feb 2004
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acetyl-l-carnitine in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by University of Wisconsin–Madison. Primary endpoint: Overall Response Rate at 24 weeks. Started Feb 2004; status: completed.
02
Drugs
acetyl-l-carnitine
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT00581919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00581919.